Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo.
Deoxycoformycin (DCF), an adenosine deaminase (ADA) inhibitor, has been shown to be active in lymphoid neoplasms. The mechanism of cytotoxicity might involve accumulation of deoxyadenosine triphosphate (dATP), depletion of the nicotinamide adenine dinucleotide (NAD) and ATP pool, induction of double-stranded DNA strand breaks, or inhibition of S-adenosyl homocysteine hydrolase (SAH-hydrolase). We have investigated the biochemical changes in the circulating malignant cells of patients with chronic leukemia/lymphoma who were treated with DCF (4 mg/m2 weekly). Blood samples were taken from 17 patients with 60% or more circulating leukemic cells before, 4, 24, and 48 hours and five days after the first administration of DCF. Leukemic cells were separated and studied for changes in ADA, dATP, ATP, NAD, and SAH-hydrolase levels and DNA strand breaks and the data analyzed according to clinical response. Inhibition of ADA activity was found in all except one patient at 4 to 24 hours after the first administration of DCF. dATP started to accumulate at four hours, reached a maximum level between 24 and 48 hours, and returned to base values on the fifth day. Intracellular ATP and NAD levels were transiently reduced in some of the patients. However, no correlation between these changes and a clinical response could be found. DNA strand breaks could be studied in 13 patients. A significant increase in DNA breaks at 24 to 48 hours was found in six of the seven responders but only in one of the six nonresponders. At 24 hours, SAH-hydrolase levels were reduced in all seven responders studied, but only in two of the seven nonresponders. The difference in inhibition of SAH-hydrolase was statistically significant (P = .0023). These results suggest that DNA strand breaks and inhibition of SAH-hydrolase correlate with clinical response.
Ho
A D
AD
Department of Internal Medicine V and Poliklinik, University of Heidelberg, Federal Republic of Germany.
Ganeshaguru
K
K
Knauf
W U
WU
Dietz
G
G
Trede
I
I
Hunstein
W
W
Hoffbrand
A V
AV
D058892:Adenosine Deaminase Inhibitors; D043383:Adenosylhomocysteinase; D003070:Coformycin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000032:analysis; D004341:Drug Evaluation; D006801:Humans; D006867:Hydrolases / Q000097:blood; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D007958:Leukocyte Count; D009363:Neoplasm Proteins / Q000097:blood; D009360:Neoplastic Cells, Circulating; D009711:Nucleotides / Q000097:blood; D015649:Pentostatin; D012263:Ribonucleosides / Q000627:therapeutic use*; D012751:Sezary Syndrome / Q000188:drug therapy*
D058892:Adenosine Deaminase Inhibitors; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D009711:Nucleotides; D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin; D006867:Hydrolases; D043383:Adenosylhomocysteinase